Summary
• DiaMedica Therapeutics Inc. (DMAC) stock rose 6.5% to $9.19 in after-hours trading, with no specific news driving the increase.
• The company reported third-quarter earnings, with an EPS of -$0.17, showing a surprise against an estimate of -$0.15 and maintaining a “Buy” analyst rating.
• DMAC shares have had significant volatility, including a 29.3% quarterly increase but a 15.7% monthly decline, alongside higher trading volume.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) saw its stock rise to $9.19 in after-hours trading, up 6.5% from its previous close of $8.63. The increase occurred without a defined catalyst, as there were no fresh news items impacting prices in the last 24 hours.
Earnings Context and Performance Update
On November 12, DiaMedica reported its third-quarter financial results, which included an actual earnings per share (EPS) of -$0.17, compared to an estimate of -$0.15, resulting in a surprise of 13%. Previously, the company recorded an EPS of -$0.18 in August. The earnings performance highlights have contributed to a current analyst rating of “Buy.”
Despite the lack of immediate news, the recent earnings report has kept investors engaged as they assess the company’s ongoing focus on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. Management provided a business update alongside the earnings report and has scheduled a conference call to further discuss their strategy.
Market and Technical Picture
The performance metrics offer insight into the stock’s dynamics. With a 14-day Relative Strength Index (RSI) of 74.23, DMAC is entering an overbought territory, suggesting recent buy-side momentum. The average volume over the past 10 days stands at 703,838 shares, comparatively higher than the three-month average of 409,818 shares, indicating increased trading activity.
Shares have shown a quarterly performance increase of 29.3% and are up 60.4% over the past six months. However, the stock has faced significant volatility, including a 16.2% decline in weekly performance and a monthly decrease of 15.7%. DMAC’s share price also sits considerably below its 52-week low, reflecting fluctuations that have been typical for the stock recently.
Closing Thoughts
With the after-hours reaction reflecting ongoing interest in DiaMedica’s financial positioning, investors will be monitoring trading volume and momentum as they consider the implications of the last earnings update. The stock’s current movement highlights traders’ ongoing assessment of the company’s growth trajectory amid routine market conditions.